Business Context and Reporting Period
This Form 8-K Current Report was filed by NeuroBo Pharmaceuticals, Inc. (not Metavia Inc.) on November 6, 2023, covering events occurring on November 1, 2023. The filing details the appointment of a new independent director to the Company's Board of Directors.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on corporate governance changes and director compensation arrangements.
Material Changes
The primary material change is the appointment of James P. Tursi, M.D., effective November 1, 2023, as a Class I Director. Dr. Tursi was also appointed to the Nominating and Corporate Governance Committee. The Board determined Dr. Tursi is independent under Nasdaq listing standards.
Compensation and Governance Details
- Initial Equity Grant: 25,000 Restricted Stock Units (RSUs) under the 2022 Equity Incentive Plan. Vesting schedule: 50% on grant date, remaining 50% in two equal installments on subsequent anniversaries.
- Cash Retainers: $40,000 annual retainer for Board service and $5,000 annual retainer for Nominating Committee service (pro-rated for the remainder of 2023).
- Annual Equity Grant: Eligible for 12,500 RSUs annually, granted 30 days after the annual stockholder meeting.
- Indemnification: Dr. Tursi will enter into the Company's standard director indemnification agreement.
Investor Verification Checklist
- Verify the exact vesting schedule and cliff dates for the 25,000 initial RSUs granted to Dr. Tursi.
- Confirm the pro-rated cash compensation amount for the remainder of calendar year 2023.
- Review the updated composition of the Audit, Compensation, and Nominating Committees as detailed in Item 8.01.
- Check the Company's 2022 Equity Incentive Plan for any limitations on total director grants.